pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-921 |
Genomic Coordinates | chr1: 166154743 - 166154798 |
Synonyms | MIRN921, hsa-mir-921, MIR921 |
Description | Homo sapiens miR-921 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-921 | ||||||||||||
Sequence | 2| CUAGUGAGGGACAGAACCAGGAUUC |26 | ||||||||||||
Evidence | Experimental | ||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
||||||||||
SNPs in miRNA |
|
||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | G2E3 | ||||||||||||||||||||
Synonyms | KIAA1333, PHF7B | ||||||||||||||||||||
Description | G2/M-phase specific E3 ubiquitin protein ligase | ||||||||||||||||||||
Transcript | NM_017769 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on G2E3 | |||||||||||||||||||||
3'UTR of G2E3 (miRNA target sites are highlighted) |
>G2E3|NM_017769|3'UTR 1 AATGTTTCCTTGAACAAAGAGAAGCTTCTTTAAAAGCTGCTATTGATAACTCTCTTTTATTTCACTAACCTTTTCATCAT 81 CACTTTGAACAAACTAGTTAGCTTCTTGACCTAATAAAATTTATGATATGAATATAAAGGAATATTATAGCCACTTAGGC 161 TAAAAAAAGGTTTTTTTTGTTAAAGCATACTAGTCAAAATTGGTGATAATTTCTCATTTTCTTGATATAGATACTTCATA 241 AACCTCAATATAAATACTCTCAAAATGGTTGTATGGATTTTATTTAGGTATGGTAGCATGGTTAATAAAAGTAAAAACTG 321 TTTTACTCACATTTTTTGTAAATTAGGATTACATATAGAATGCCACAATTTCTCTAGGTTTATTCAATTTTCAAATTATT 401 CCTCATTTTATTTTAAAGCATTAAATAGAAAAGCTAATTGGTTAAATTTTGTTATATAAATCAGAGTCATATATTCTGGG 481 ATTTGTGTTACTATGCATACTTTTCTAGGATGTCACCAAATTAGTTGTTTAAAATGTTTTTAGATTACTGATTTATATTA 561 AGATGACCCACACTGCAATTAGATTATGCCTAGTGGGAAGTATTATATAAAAAGCAGAATTAAGCTGGGCACATGTGCTT 641 GTAATCTCAGTTATAAGGGAGGCTGAGGTGGGAGAATCGAGATACTCAGCCAGCCTGGCAATGTAGCAAAGACTCCATCT 721 CAAAAAAAAAAACAGAATTGCACAAATTTTCTGGAATCTATGGACATTCCATGAGCTTAAACACTTTTGAGGTGGATAAC 801 ATTTAGTTGAAAATACCTAAGAAAGTGTGTCTTCTTTAAAGCCTTGGCTTTAATCATGGGAAATTGTTGTTGTTGTTGTT 881 GTTGTTTGTATCCTATGTTTGGTATTCTGTATGTCTGATCCATAATCATTTTAGATATTTGAATGATCTCTGTGGATTGG 961 TAGGTTTGGCCATTTGACCATTATTTATTATCAAGTTGGTTGTATGCTAAGGTAAGTTGACGCCATAGCATTATACAGTT 1041 ATCTTCATTGCTCTTGAATGATATCTGTTATATAAGCAATGTATAAATAAAGTAAAAAGGATAGAATGAAAAACCCATTC 1121 TAATGTCACCACTCAGAGATAAGTACCGTATTTCTGTGTATCCTTCTATAAACTCTTTACTTCTGTTTCCTTTATTTTTT 1201 AACTTTAATAATGCTACTAAAAGACAATACCTAAAAGTAACTGTACTAACAAAGTGCTAACAATGTGAAAATATATAGTC 1281 CCATAGTCATGTCCCCATATTTATACTCCCACAGAAGAAAAAATTGGAAAACAAAGTCTGATGTCCTTAATCTATTAACA 1361 TATTTAAATGATATAATGGTTCAGTTTTCCATGAAAGTAAATCATTATGGGAAGTAAAATGTTTTAACCATATTTTTCTT 1441 AATACACAAAGCAGGTGTCAGCTGTTGTATTCTCACCCTTCTTAAGAAAAATCATTACATTATTGATATTTTTTAAGTAA 1521 CAGAATAGATTTGAAAGAGATAATATATCTCTTAATACCAAAGGAAAACTAAAACATAATTCTAGTGTACTTTTCTTTGT 1601 TCCCTCATGTCTTTTTCAATCTGTACACTAACATACCTAGCAAATTTGTTTTACTTTAACTTGAAATATTTAAGAACATT 1681 AAACAAGACATTTCTTTGGCTTTGGTTGAATTTTTTTGTCTCACCAATAGTAATTGAAAGATCAATTATCAAAGAGTTTG 1761 AATAGCTAATATAAACCCCAAAGTCACCATACAGTTTTTATTCCAAATATGTTGATAAAAAGATATTTGTTTCTTTATCC 1841 ACCTTATTTTTATTACAGCTAAAAACCAATACAAACCAATAAAACCTAGTTAAAGCTATTTTCTGGTTTTTAGTTGCAAT 1921 TAATTTCCCCTAGGGTAGAAATTAAAGCTGATTAAGTCACACACACATACTTTGTTGGGGTGGGGGTGGCAGGTGGAGAG 2001 GCAGTGTACTTGGGTTAGCTACAATTAAAAACAGTATTTCAATTCCTCATTTGACTTATTTTATATATAGACAGGGCCTT 2081 AGTGATAAGATGGTGTAAATAATTTAGGATATTCATGTTTTAAAGTGAAGCATAAATATTTATTTTGCAAAATGTTTTCT 2161 AGTTTGAAGGATGTTCCATTATTACCATTTTTAGATTAATCTGTATGGTCAAGGAATATCAGAGAAACCTGTAGGTTATT 2241 TATTTTCTGCAGTGTCATTTTGTCAAATGGTTGGTATTATAATTGTTCTTTTCTTATTAATTTTATAACCAGTGCATAAT 2321 TCTTACATTAGATTTTAAAAAAGAATTATGCTATAAATCTTTATAAATGTGTACATATATTTCTTAAATATTGCAATTGC 2401 CTAAATGTTGTATATTTTAAGGCTGTTTTCTCTTGCTCTTAATGTTGAGGAAAACTATAAATTGATCTATAATGCATCTA 2481 CTGTTAATGGTTTTGGTTAGTTTGATATTCATTGTTTTTAAACACTTTCCAATATGGAAACTTTAACACCTTTTATACAA 2561 TTCTCTACTATTCAAGATATTCTTTAAAATATCTCACCAGAAACTTACAATTTTATACTTTGTAATTTTTAGTTTCTGTA 2641 ATTTGAGGAAGTGACTTTTTTTGTTTGGGTTAAGTAAAAAGCCTTTGATTGATTACCAGCATGAGAATTCACCTTGGTTT 2721 CTATTTTATGCATTTGTAAATTTTTCCCCTAATTATATGGAAGCTATTGGAACTTTTGTATTCAGTGCTAAATACTAAGT 2801 CAAGGGGAGTATATTAGGTAAGTTTTTTCAGTGACTGTGCCTTTAGCATTCAGTCATTATAAGAAAATGATCAGAACAAA 2881 ATCATTACATTATAAACATGTAATTCTTTTATATAGTGATTATCATGTACTGCATTGTTACTTTAAAATAAGCTATTAAA 2961 CTAGTTTTTATGGTTCAAGTAATGCAATACAAAGTTTCATGCTTCAAGTAATGCAATACAAAACATAACCCATTTAATGA 3041 TGAATTACTTGAATGTATATTATCTGTGGTTTAGGAAAATTTGGATTGTCTTGAAGAGACTCAGTTTTCAAGTTCTGATT 3121 TTGACCATTATCTCTTCTAATTCATAAACATATCCCAGTACCTACACTATGCCAGGTATTATGCTAGGTGATCGTTTATA 3201 TGTCAGCCTATTTCCCCCCCTTTTAAAGACTGCCAGATTAACCAAAAAGCGTGACATTTATAACAATGTTTTATAAATAA 3281 ATAAATGTGTTTATGCCACTAAAGGTAAACTGCCTATTTAAACTAAGTAATTTTTTGGGATTTAATAAGATTAAGATTCT 3361 GACGAAACTGAAAGATACAAGATTCCTTTACTCTCCACATTTGAGAGATCCTATAAGCAAGCAGTTAGTGTCTGACACCC 3441 AGGAACCTATAGAAATGAGGGAATCTGTGTTAAAACTATGTATCCTCTAATGTAAAATAGCTTACCAGAATAAATTATTT 3521 AAGCCAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000206595.6 | 3UTR | UCACUAACCUUUUCAUCAUCACUUUGAACAAACUAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
63 hsa-miR-921 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT054764 | ANGPTL1 | angiopoietin like 1 | 3 | 1 | ||||||||
MIRT066171 | PIP4K2C | phosphatidylinositol-5-phosphate 4-kinase type 2 gamma | 2 | 2 | ||||||||
MIRT069409 | ZFYVE21 | zinc finger FYVE-type containing 21 | 2 | 8 | ||||||||
MIRT102284 | DNAJB9 | DnaJ heat shock protein family (Hsp40) member B9 | 2 | 4 | ||||||||
MIRT107595 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | 2 | 6 | ||||||||
MIRT178618 | HIAT1 | major facilitator superfamily domain containing 14A | 2 | 2 | ||||||||
MIRT182407 | TIPRL | TOR signaling pathway regulator | 2 | 4 | ||||||||
MIRT186552 | ZBTB18 | zinc finger and BTB domain containing 18 | 2 | 2 | ||||||||
MIRT273662 | HOXC8 | homeobox C8 | 2 | 2 | ||||||||
MIRT283191 | C16ORF52 | chromosome 16 open reading frame 52 | 2 | 2 | ||||||||
MIRT284890 | NFAT5 | nuclear factor of activated T-cells 5 | 2 | 2 | ||||||||
MIRT347670 | LSM14A | LSM14A, mRNA processing body assembly factor | 2 | 2 | ||||||||
MIRT400222 | SLC35F6 | solute carrier family 35 member F6 | 2 | 2 | ||||||||
MIRT403517 | ASPH | aspartate beta-hydroxylase | 2 | 2 | ||||||||
MIRT442251 | DCTN5 | dynactin subunit 5 | 2 | 2 | ||||||||
MIRT443023 | SDR39U1 | short chain dehydrogenase/reductase family 39U member 1 | 2 | 2 | ||||||||
MIRT443097 | RNF20 | ring finger protein 20 | 2 | 2 | ||||||||
MIRT444560 | TRA2B | transformer 2 beta homolog | 2 | 2 | ||||||||
MIRT445696 | PRKG1 | protein kinase, cGMP-dependent, type I | 2 | 2 | ||||||||
MIRT454084 | TMEM209 | transmembrane protein 209 | 2 | 2 | ||||||||
MIRT455463 | LYPLA2 | lysophospholipase II | 2 | 2 | ||||||||
MIRT456653 | TIFA | TRAF interacting protein with forkhead associated domain | 2 | 2 | ||||||||
MIRT458147 | LYRM4 | LYR motif containing 4 | 2 | 6 | ||||||||
MIRT467073 | SRRD | SRR1 domain containing | 2 | 4 | ||||||||
MIRT467245 | SPPL2A | signal peptide peptidase like 2A | 2 | 2 | ||||||||
MIRT468246 | SFXN4 | sideroflexin 4 | 2 | 2 | ||||||||
MIRT471589 | PAQR5 | progestin and adipoQ receptor family member 5 | 2 | 19 | ||||||||
MIRT476639 | G2E3 | G2/M-phase specific E3 ubiquitin protein ligase | 2 | 2 | ||||||||
MIRT482433 | ADM | adrenomedullin | 2 | 10 | ||||||||
MIRT486848 | PERP | PERP, TP53 apoptosis effector | 2 | 6 | ||||||||
MIRT489656 | SHMT1 | serine hydroxymethyltransferase 1 | 2 | 2 | ||||||||
MIRT493441 | KANSL1 | KAT8 regulatory NSL complex subunit 1 | 2 | 6 | ||||||||
MIRT493841 | FOXN3 | forkhead box N3 | 2 | 4 | ||||||||
MIRT501378 | RBFOX2 | RNA binding protein, fox-1 homolog 2 | 2 | 10 | ||||||||
MIRT509679 | ATAD5 | ATPase family, AAA domain containing 5 | 2 | 4 | ||||||||
MIRT510280 | MED28 | mediator complex subunit 28 | 2 | 2 | ||||||||
MIRT512221 | ATXN3 | ataxin 3 | 2 | 6 | ||||||||
MIRT514030 | BNIP2 | BCL2 interacting protein 2 | 2 | 2 | ||||||||
MIRT521375 | RDX | radixin | 2 | 4 | ||||||||
MIRT521444 | RAD51 | RAD51 recombinase | 2 | 2 | ||||||||
MIRT526055 | CBR1 | carbonyl reductase 1 | 2 | 2 | ||||||||
MIRT528658 | FUNDC2 | FUN14 domain containing 2 | 2 | 2 | ||||||||
MIRT529975 | TNFAIP8L1 | TNF alpha induced protein 8 like 1 | 2 | 2 | ||||||||
MIRT544098 | IPMK | inositol polyphosphate multikinase | 2 | 2 | ||||||||
MIRT545579 | SNRPA1 | small nuclear ribonucleoprotein polypeptide A' | 2 | 2 | ||||||||
MIRT547424 | MED4 | mediator complex subunit 4 | 2 | 2 | ||||||||
MIRT548955 | CD2AP | CD2 associated protein | 2 | 2 | ||||||||
MIRT549537 | NDUFA6 | NADH:ubiquinone oxidoreductase subunit A6 | 2 | 4 | ||||||||
MIRT552550 | ZFP36L2 | ZFP36 ring finger protein like 2 | 2 | 4 | ||||||||
MIRT554640 | ROBO1 | roundabout guidance receptor 1 | 2 | 2 | ||||||||
MIRT564904 | YTHDF1 | YTH N6-methyladenosine RNA binding protein 1 | 2 | 2 | ||||||||
MIRT565578 | SLC6A8 | solute carrier family 6 member 8 | 2 | 2 | ||||||||
MIRT568312 | BAG4 | BCL2 associated athanogene 4 | 2 | 2 | ||||||||
MIRT617891 | PTCHD3 | patched domain containing 3 | 2 | 2 | ||||||||
MIRT621892 | TAF13 | TATA-box binding protein associated factor 13 | 2 | 2 | ||||||||
MIRT642850 | RNF135 | ring finger protein 135 | 2 | 2 | ||||||||
MIRT665395 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 2 | ||||||||
MIRT697879 | UBE2B | ubiquitin conjugating enzyme E2 B | 2 | 2 | ||||||||
MIRT698492 | THOC2 | THO complex 2 | 2 | 2 | ||||||||
MIRT701227 | OCRL | OCRL, inositol polyphosphate-5-phosphatase | 2 | 2 | ||||||||
MIRT701872 | MPLKIP | M-phase specific PLK1 interacting protein | 2 | 2 | ||||||||
MIRT707045 | TRPV2 | transient receptor potential cation channel subfamily V member 2 | 2 | 2 | ||||||||
MIRT715216 | NPVF | neuropeptide VF precursor | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|